Timothy Clay

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Takuya Osada, Gabriel T. Chong, Robert L. Tansik et al. · Cancer Immunology Immunotherapy · 2008 · 310 citations · Full text

Medicine, Immunology, Oncology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

Michael A. Morse, Robert Chapman, John D. Powderly et al. · Clinical Cancer Research · 2011 · 141 citations · Full text

Medicine, Immunology, Oncology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity

Takuya Osada, Timothy Clay, Amy Hobeika et al. · Cancer Immunology Immunotherapy · 2005 · 71 citations · Full text

Life Sciences, Cell Biology, Immunology +13